Pulmonary hemorrhage in systemic lupus erythematosus

Lupus. 1997;6(5):445-8. doi: 10.1177/096120339700600506.

Abstract

In order to assess the clinical characteristics and survival rate of pulmonary hemorrhage (PH) in systemic lupus erythematosus (SLE), we studied SLE patients who developed this complication. We found 34 patients within a total lupus cohort of 630 patients. All the patients had severe respiratory failure. We identified three different treatment regimens: (a) oral prednisone (1 mg/kg); (b) conventional methylprednisolone (3 g total dose) and (c) massive methylprednisolone (> 4 g). The overall survival rate was 38.2% and it was correlated with the massive regimen and early treatment (within the first 48 h after the onset of the acute event).

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Autoimmune Diseases / complications*
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / therapy
  • Cohort Studies
  • Comorbidity
  • Cyclophosphamide / therapeutic use
  • Drug Administration Schedule
  • Female
  • Hemoptysis / etiology
  • Hemorrhage / drug therapy
  • Hemorrhage / etiology*
  • Hemorrhage / mortality
  • Hemorrhage / pathology
  • Hemorrhage / therapy
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases / drug therapy
  • Lung Diseases / etiology*
  • Lung Diseases / mortality
  • Lung Diseases / pathology
  • Lung Diseases / therapy
  • Lupus Erythematosus, Systemic / complications*
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / therapy
  • Male
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / therapeutic use
  • Mexico / epidemiology
  • Plasma Exchange
  • Plasmapheresis
  • Pneumonia / drug therapy
  • Pneumonia / epidemiology
  • Prednisone / administration & dosage
  • Prednisone / therapeutic use
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Immunosuppressive Agents
  • Cyclophosphamide
  • Prednisone
  • Methylprednisolone